Could the Darwinian approach to drug discovery be the next era for cancer treatment?

With focus on a ‘Darwinian’ approach, the Institute of Cancer Research (ICR; London, UK) launch their new drug discovery program that aims to target cancer’s lethal ability to evolve resistance to current treatments.For millions of years the Darwinian theory of natural selection has benefited Homo sapiens, allowing humans to develop from the smallest of organisms. However, ICR scientists now say survival of the fittest has been replaced by “survival of the nastiest”, as cancer cells evolve and become more resistant to current cancer treatments. “Cancer’s ability to adapt, evolve and become drug resistant is the cause of the vast majority...